Browse All

Current Filters

CLEAR FILTER x

TITLE

Title
    Author Last Name
      Session Name
        Topic
          Program Number
            Author Institution

              Zavegepant 10 mg Nasal Spray is Effective for the Acute Treatment of Migraine Regardless of Attack Frequency: Pooled Results From 2 Randomized, Placebo-Controlled Clinical Trials

              Author:Pavlovic, Jelena   Smith, Timothy   Mullin, Kathleen   Joshi, Shivang   Croop, Robert   Madonia, Jennifer   Mosher, Linda   Lovegren, Meghan   Forshaw, Micaela   Lipton, Richard   

              Session Name:S47: Advances in Migraine Therapeutics  

              Topic:Headache  

              Program Number:S47.003  

              Author Institution:Albert Einstein College of Medicine, Bronx, NY  StudyMetrix Research, Saint Louis, MO  New England Institute for Neurology and Headache, Stamford, CT  Community Neuroscience Services, Westborough, MA  Biohaven Pharmaceuticals, Wynnewood, PA  Biohaven Pharmaceuticals, New Haven, CT  Biohaven Pharmaceuticals, Wallingford, CT  

              Zavegepant Nasal Spray for the Acute Treatment of Migraine With Aura and Without Aura: Pooled Results From 2 Randomized, Placebo-Controlled Clinical Trials

              Author:Smith, Timothy   Pavlovic, Jelena   Mullin, Kathleen   Joshi, Shivang   Croop, Robert   Madonia, Jennifer   Mosher, Linda   Lovegren, Meghan   Forshaw, Micaela   Lipton, Richard   

              Session Name:S47: Advances in Migraine Therapeutics  

              Topic:Headache  

              Program Number:S47.004  

              Author Institution:StudyMetrix Research, Saint Louis, MO  Albert Einstein College of Medicine, Bronx, NY  New England Institute for Neurology and Headache, Stamford, CT  Community Neuroscience Services, Westborough, MA  Biohaven Pharmaceuticals, Wynnewood, PA  Biohaven Pharmaceuticals, New Haven, CT  Biohaven Pharmaceuticals, Wallingford, CT  

              Significant reduction in migraine days with Remote Electrical Neuromodulation (REN) for migraine prevention: A double-blind randomized sham-controlled clinical trial

              Author:Tepper, Stewart   Rabany, Liron   Cowan, Robert   Smith, Timothy   Grosberg, Brian   Torphy, Brad   Harris, Dagan   Vizel, Maya   Ironi, Alon   Stark-Inbar, Alit   Garas, Sandy   Blumenfeld, Andrew   

              Session Name:S47: Advances in Migraine Therapeutics  

              Topic:Headache  

              Program Number:S47.010  

              Author Institution:Geisel School of Medicine At Dartmouth, Lebanon, NH  Theranica Bio-Electronics Ltd., Natanya, Israel  Stanford Neurosciences Health Center, Palo Alto, CA  StudyMetrix Research, Saint Louis, MO  Hartford HealthCare Headache Center, West Hartford, CT  Chicago Headache Center and Research Institute, Chicago, IL  Theranica BioElectronics Ltd, Netanya, Israel  Theranica Bio-Electronics, Netanya, Israel  Theranica, Netanya, Israel  Theranica Bio-Electronics, MONTCLAIR, NJ  Theranica USA, Montclair, NJ  The Los Angeles and San Diego Headache Centers, San Diego, CA  

              Efficacy of Zavegepant Nasal Spray for the Acute Treatment of Migraine Based on Triptan Treatment Experience: Pooled Results From 2 Randomized, Placebo-Controlled Clinical Trials

              Author:Joshi, Shivang   Smith, Timothy   Pavlovic, Jelena   Mullin, Kathleen   Croop, Robert   Madonia, Jennifer   Mosher, Linda   Lovegren, Meghan   Forshaw, Micaela   Lipton, Richard   

              Session Name:P9: Headache: The Gepant Pipeline  

              Topic:Headache  

              Program Number:P9.003  

              Author Institution:Community Neuroscience Servicese, Westborough, MA  StudyMetrix Research, Saint Louis, MO  Albert Einstein College of Medicine, Bronx, NY  New England Institute for Neurology and Headache, Stamford, CT  Biohaven Pharmaceuticals, Wynnewood, PA  Biohaven Pharmaceuticals, New Haven, CT  Biohaven Pharmaceuticals, Wallingford, CT  

              Long-Term Safety and Tolerability of Zavegepant 10 mg Nasal Spray During Concomitant Use of CGRP Monoclonal Antibodies: Results From a 1-Year Open-label Safety Trial

              Author:Berman, Gary   Mullin, Kathleen   Pavlovic, Jelena   Smith, Timothy   Croop, Robert   Madonia, Jennifer   Mosher, Linda   Hould, Jennifer   Lipton, Richard   

              Session Name:P10: Headache: Towards Precision Medicine 1  

              Topic:Headache  

              Program Number:P10.009  

              Author Institution:Clinical Research Institute , Minneapolis, MN  New England Institute for Neurology and Headache, Stamford, CT  Albert Einstein College of Medicine, Bronx, NY  StudyMetrix Research, Saint Louis, MO  Biohaven Pharmaceuticals, Wynnewood, PA  Biohaven Pharmaceuticals, New Haven, CT  Biohaven Pharmaceuticals, Wallingford, CT